{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:18:30Z","timestamp":1790813910692,"version":"4.1.0"},"reference-count":39,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2018,10,16]]},"abstract":"<jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Background\/Objective:<\/jats:title>\n                    <jats:p>To assess associations between improvements in neuropsychiatric symptoms (NPS) and neurocognitive change in patients with Alzheimer\u2019s disease (AD) during treatment using the Clinical Antipsychotic Trials of Intervention Effectiveness\u2013Alzheimer Disease (CATIE-AD) dataset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      AD outpatients with NPS who needed pharmacological treatment (\n                      <jats:italic>n<\/jats:italic>\n                      \u200a=\u200a421) were followed up with antipsychotics, citalopram, or placebo for up to 36 weeks (mean\u00b1SD\u200a=\u200a252\u00b152 days). The study aim was to investigate associations between improvement in each NPS evaluating scale (by Clinical Global Impression of Change [CGI-C], Neuropsychiatric Inventory [NPI], or Brief Psychiatric Scale [BPRS]) at endpoint (week 36 or early termination [ET],\n                      <jats:italic>n<\/jats:italic>\n                      \u200a=\u200a340) and neurocognitive change (change score in the Mini-Mental State Examination [MMSE] between endpoint and baseline during the treatment). Multiple logistic regression analyses were performed on the associations between each NPS improvement and neurocognitive change as well as socio-clinico-demographic variables of interest.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>At endpoint, NPS improvement rates were 76.1%, 70.8%, and 58.1% in CGI-C, NPI, and BPRS, respectively, while MMSE score change was \u20132.3\u00b13.8. NPS improvement was significantly related to more severe psychotic symptoms at baseline and preserved levels of neurocognition (smaller MMSE score change) among several variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our findings suggested that neurocognitive preservation may be associated with attaining optimal benefits from any treatment against NPSs in a longitudinal treatment course of patients with AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jad-180304","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T13:40:16Z","timestamp":1537537216000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer\u2019s Disease: Analysis of the CATIE-AD Study"],"prefix":"10.1177","volume":"66","author":[{"given":"Tomoyuki","family":"Nagata","sequence":"first","affiliation":[{"name":"Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Shinagawa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Shigeta","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610205002292"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610208006777"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.130"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000084552"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061240"},{"key":"e_1_3_1_8_2","first-page":"1264","article-title":"Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer\u2019s disease needing interventional treatment: Analysis of the CATIE-AD study","volume":"232","author":"Nagata T","year":"2016","unstructured":"NagataT, NakajimaS, ShinagawaS, PlitmanE, Graff-GuerreroA, MimuraM, NakayamaK (2016) Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer\u2019s disease needing interventional treatment: Analysis of the CATIE-AD study. Int J Geriatr Psychiatry 232, 1264\u20131271.","journal-title":"Int J Geriatr Psychiatry"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2006.03.002"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.11.2022"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170412"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200111000-00004"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.5_Suppl_6.10S"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2012.10.013"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301147"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00004"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00005"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb07245.x"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/20.6.649"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000091790"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-161264"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.7.857"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106668"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.93"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2630"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114058"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-161023"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181e446c8"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.14040480"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160767"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.13037"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2007.07.007"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066583"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-142508"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.4.527"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.12.001"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000338233"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.08121844"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-180304","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-180304","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-180304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:06Z","timestamp":1777370886000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-180304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,10,16]]}},"alternative-id":["10.3233\/JAD-180304"],"URL":"https:\/\/doi.org\/10.3233\/jad-180304","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]}}}